Table 1– Demographic and clinical profile by the extensively drug-resistant tuberculosis (XDR-TB) patient group
XDR aloneXDR+2sliXDR+sliG4XDR+sliG4EZ
Subjects n301684842
Age years40.7±13.542.3±14.440.5±15.846.1±16.6
Male62665657
HIV infection#22148
Sputum smear positive78807874
Cavities on chest radiography74867875
Extensive disease78787471
Pulmonary TB only9895100100
Prior treatment
 None18241618
 First-line drugs58376762
 Second-line drugs25391821
  • Data are presented as mean±sd or %, unless otherwise stated. Percentages do not always total 100% due to rounding. XDR alone: resistance to isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drug (sli); XDR+2sli: XDR-TB plus resistance to both an aminoglycoside injectable (kanamycin/amikacin) and to capreomycin; XDR+sliG4: XDR-TB, plus resistance to all second-line tuberculosis drugs tested, with, as a minimum, resistance to kanamycin and to at least one group 4 drug (G4); XDR+sliG4EZ: XDR-TB, plus resistance to all first- and second-line TB drugs tested, with, as a minimum, resistance to kanamycin, one group 4 drug and either pyrazinamide (Z) and/or ethambutol (E). #: percentage of patients who were tested; not all were tested; : defined as sputum smear-positive on direct microscopy or in the absence of smear information, with cavities on chest radiography (see Methods section).